SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-359368"
 

Sökning: id:"swepub:oai:DiVA.org:uu-359368" > Reporting of patien...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004524naa a2200457 4500
001oai:DiVA.org:uu-359368
003SwePub
008180904s2018 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3593682 URI
0247 a https://doi.org/10.1016/j.ejca.2018.03.0262 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a for2 swepub-publicationtype
1001 a Goey, Kaitlyn K. H.u Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands4 aut
2451 0a Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer :b A systematic review
264 1b Elsevier BV,c 2018
338 a print2 rdacarrier
520 a Background: Patient characteristics and stratification factors are important factors influencing trial outcomes. Uniform reporting on these parameters would facilitate cross-study comparisons and extrapolation of trial results to clinical practice. In 2007, standardisation on patient characteristics reporting and stratification in metastatic colorectal cancer (mCRC) trials was proposed. We investigated the reporting of prognostic factors and implementation of this proposal in mCRC trials published from 2005 to 2016.Methods: We searched PubMed and Embase (January 2005 – June 2016) for first-line phase 3 mCRC trials. Patient characteristics reporting and use of stratification factors were extracted and analysed for adherence to the proposal from 2007.Results: Sixty-seven trials (35,315 patients) were identified, reporting 48 different patient characteristics (median: 9 [range: 5–18] per study). Age, gender, performance status (PS), primary tumour site and adjuvant chemotherapy were frequently reported (87%–100%), in contrast to laboratory values, such as alkaline phosphatase, lactate dehydrogenase and white blood cell count (10%–25%). We identified 29 different stratification factors (median: 3 [range: 1–9] per study). The most common strata were PS and treatment centre (>60%). A median of 8/12 (range: 4–11) of the proposed parameters was reported. Although the percentage of studies reporting each factor slightly increased over time, there was no significant correlation between publication year and adherence to the proposal from 2007.Conclusions: We observed persistent heterogeneity in the reporting of patient characteristics and use of stratification factors in first-line mCRC trials. The proposal from 2007 has not led to increased uniformity of patient characteristics reporting and use of stratification over time. There is an urgent need to address this issue to improve the interpretation of trial results.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Colorectal cancer
653 a Metastatic disease
653 a Patient characteristics
653 a Prognosis
653 a Stratification
653 a Systematic review
653 a Clinical trials
7001 a Mahmoud, Remiu Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands4 aut
7001 a Sørbye, Halfdanu Haukeland Hosp, Dept Oncol, Bergen, Norway; Haukeland Hosp, Dept Clin Sci, Bergen, Norway4 aut
7001 a Glimelius, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)bengglim
7001 a Köhne, Claus-Henningu Klinikum Oldenburg, Univ Clin Internal Med Oncol & Hematol, Oldenburg, Germany4 aut
7001 a Sargent, Daniel J.u Mayo Clin, Ctr Canc, Div Biomed Stat & Informat, Rochester, MN USA4 aut
7001 a Punt, Cornelis J. A.u Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, Amsterdam, Netherlands4 aut
7001 a van Oijen, Martijn G. H.u Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, Amsterdam, Netherlands4 aut
7001 a Koopman, Miriamu Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands4 aut
7102 a Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlandsb Haukeland Hosp, Dept Oncol, Bergen, Norway; Haukeland Hosp, Dept Clin Sci, Bergen, Norway4 org
7730 t European Journal of Cancerd : Elsevier BVg 96, s. 115-124q 96<115-124x 0959-8049x 1879-0852
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-359368
8564 8u https://doi.org/10.1016/j.ejca.2018.03.026

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy